Abstract library

1728 results for "tumor location".
#141 Incidence of second primary tumors in patients with neuroendocrine tumors
Introduction: Based on epidemiological data from SEER 1950-1999, 22.4% cases of non-carcinoid second primary tumors have been described in patients diagnosed with neuroendocrine tumors. The incidence of this type of tumors varies, depending on the series assessed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Juan Manuel OConnor
Authors: Pesce V, OConnor J, Mendez G, Bestani C, ...
#907 The Neuroendocrine Tumor in Choroid: An Unusual Metastatic Location (Clinical Case Report)
Introduction: Neuroendocrine neoplasms are tumors of various location and symptoms. This case shows the unusual choroidal location of the metastatic NEN.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: M.D. Jaroslava Barkmanova
#1133 Prognosis of Stage IV Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) According to the WHO Classification and the Primary Tumor Location
Introduction: WHO classification of GEP-NET is used to predict prognosis, yet survival within each grade shows wide variation. We hypothesized that primary tumor location may be partially responsible of this variability.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: PhD Paula Jiménez-Fonseca
#68 Serum chromogranin A as tumor marker in neuroendocrine tumors
Introduction: Serum chromogranin A (CgA) is used as a tumor marker for neuroendocrine tumors (NETs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Svenja Nölting
#397 Swiss Neuroendocrine Tumor (SwissNET) Registry: Update After Three Years
Introduction: To improve epidemiological data on patients with neuroendocrine tumors (NETs) in Switzerland, the Swiss registry for NETs (SwissNET) was established in 2008. Here we present the current state of the registry in 2011.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Professor Christoph Stettler
#2111 Biliary Neuroendocrine Tumors: A Retrospective Analysis of 28 Patients Since 1991
Introduction: Biliary neuroendocrine tumors represent less than 1% of all neuroendocrine tumors (NETs), and the related clinical study is limited.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Zhibo Zheng
Authors: Zheng Z, Chen C, Xie Y, Zheng C, ...
#2015 Single-Institutional Review of Non-Pancreatic GI Neuroendocrine Tumors
Introduction: Neuroendocrine tumors (NETs) most commonly occur in the digestive tract with an incidence of 3.56 per 100,000 with 94% of those being non pancreatic.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: M.D. Alaa El Chami
#681 The Use of Capsule Endoscopy for Assessment of Neuroendocrine Tumors of Unknown Primary Tumor Location
Introduction: Recent studies suggest that capsule endoscopy (CE) should be implemented in diagnostic work-up in patients suspected to have small bowel (SB) tumors. SB accounts for the primary tumor site in 80%-85% of patients with intestinal neuroendocrine tumors (NET). In 10%-15% of patients diagnosed with metastasized NET, the primary tumor site remains obscure.
Conference: 10th Annual ENETS Conference (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: PhD Panagiotis Drymousis
#1270 Clinicopathological Features and Prognostic Factors of Colorectal Neuroendocrine Neoplasms in China
Introduction: Limited research is available regarding colorectal neuroendocrine neoplasms (NENs), especially in China.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: M.D. Mengjie Jiang
Authors: Jiang M, Fu J, Tan Y, Hu H, ...
#59 Incidence and clinical significance of adrenal masses in patients with gastrenteropancreatic neuroendocrine tumors
Introduction: The widespread application of modern imaging modalities, mainly computerized tomography (CT) and magnetic resonance imaging (MRI), has revealed a 2-3% incidence of inadvertently discovered adrenal masses, the majority of which are non-functioning benign adrenal adenomas. In the presence of a known malignancy, such lesions have a more than 30% incidence of being metastases. As patients with gastrenteropancreatic neuroendocrine tumors (GEP-NETS) have mainly well-differentiated and slow-growing tumors and are subject to routine abdominal imaging for disease staging or during follow-up, it is important to study the incidence and significance of such lesions based on the recently introduced TNM classification system.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Georgios Kanakis